HFB-301001 is under clinical development by HiFiBiO Therapeutics and currently in Phase I for Renal Cell Carcinoma. According to GlobalData, Phase I drugs for Renal Cell Carcinoma have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how HFB-301001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HFB-301001 is under development for the treatment of solid tumors, soft tissue sarcoma, renal cell carcinoma, uterine carcinosarcoma, hepatocellular carcinoma and head and neck squamous cell carcinoma. It is administered through intravenous route. The drug candidate acts by targeting OX40 receptor and is developed based on drug intelligent science (DIS) platform.
HiFiBiO Therapeutics overview
HiFiBiO Therapeutics, a biotechnology company that engaged in providing antibody drug discovery services. The company is headquartered in United States.
For a complete picture of HFB-301001’s drug-specific PTSR and LoA scores, buy the report here.